Follow RSS for latest reports on this topicELIQUIS (Apixaban) - Market Research and Reports

ELIQUIS (apixaban) is an oral direct Factor Xa inhibitor.

Eliquis is an oral drug used for preventing blood clots in patients with atrial fibrillation. It is an anticoagulant that works by blocking the action of factor Xa. Factor Xa is an important protein in the coagulation cascade that causes blood to clot. Reducing the action of factor Xa reduces the ability of blood to clot. In patients with atrial fibrillation there is increased risk of blood clots which can travel to the brain where it causes strokes as well as to other organs.

BioPortfolio's Easy Ordering System

  1. Search for the report you need from our store
  2. Make online payment with our easy checkout process
  3. Receive PDF report via email

Easy Online Payment or Pro Forma Invoice

We accept the following credit cards...



or can supply a pro-forma invoice if required.

Related Reports:

We found 6 reports that matched your search.

Refine your search, and find more matches, using the form above.

Venous Thromboembolism Treatment Market: By Type (Deep Venous Thrombosis, and Pulmonary Embolism); By Treatment (Heparin, Apixaban, Dabigatran, Rivaroxaban, Edaxaban, Others) & By Region (Europe, North America, Asia-Pacific, RoW)-Forecast (2016-2022) [Report Updated: 27-09-2016]

Venous Thromboembolism (VTE) is a lethal disorder that affects the hospitalized and non-hospitalized patients, recurs frequently, and results in long-term complications including chronic thromboembolic pulmonary hypertension (CTPH) and the post-thrombotic syndrome (PTS). It includes both deep vein thrombosis (DVT) and pulmonary embolism (PE). Globally, development of efficient and advanced technol...Read More >>>

Published:
2016-09-27

Published by: Industry ARC

Prices Starting From:
$5250

Additional Searches

You may also like to search separately for: ELIQUIS (Apixaban)

We Stock...

{STICKYFOOTERMOBILE}